Regulation of CD133 by HDAC6 Promotes β-Catenin Signaling to Suppress Cancer Cell Differentiation

Cell Reports

Volumn 2, Issue 4, 2012, Pages 951-963

  Mak, Anthony B ^a   Nixon, Allison M L ^a   Kittanakom, Saranya ^a   Stewart, Jocelyn M ^a,e   Chen, Ginny I ^a,b   Curak, Jasna ^a   Gingras, Anne Claude ^a,b   Mazitschek, Ralph ^c,d   Neel, Benjamin G ^a,e   Stagljar, Igor ^a   Moffat, Jason ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; HISTONE DEACETYLASE 6; TUMOR MARKER;

ACETYLATION; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN FUNCTION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION; CELL LABELING; CELL PROLIFERATION; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENDOSOME; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LYSOSOME; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEIN TRANSPORT; STEM CELL; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY;

ACETYLATION; ANIMALS; ANTIGENS, CD; BETA CATENIN; CACO-2 CELLS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; ENDOSOMES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GLYCOPROTEINS; HEK293 CELLS; HISTONE DEACETYLASES; HT29 CELLS; HUMANS; MICE; MICE, INBRED NOD; NEOPLASMS; PEPTIDES; PROTEIN BINDING; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; WNT PROTEINS;

EID: 84868099762     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.09.016     Document Type: Article

References (39)

1. Brabletz S., Schmalhofer O., Brabletz T. Gastrointestinal stem cells in development and cancer. J. Pathol. 2009, 217:307-317.
2. Chen B., Dodge M.E., Tang W., Lu J., Ma Z., Fan C.W., Wei S., Hao W., Kilgore J., Williams N.S., et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 2009, 5:100-107.
3. Corbeil D., Röper K., Hellwig A., Tavian M., Miraglia S., Watt S.M., Simmons P.J., Peault B., Buck D.W., Huttner W.B. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J. Biol. Chem. 2000, 275:5512-5520.
4. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., Milutinovic N., Kratchmarova I., Buerkle L., Fetchko M.J., et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal. 2009, 2:ra84.
5. Elsaba T.M., Martinez-Pomares L., Robins A.R., Crook S., Seth R., Jackson D., McCart A., Silver A.R., Tomlinson I.P., Ilyas M. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS ONE 2010, 5:e10714.
6. Ferrandina G., Petrillo M., Bonanno G., Scambia G. Targeting CD133 antigen in cancer. Expert Opin. Ther. Targets 2009, 13:823-837.
7. Gao Y.S., Hubbert C.C., Yao T.P. The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J. Biol. Chem. 2010, 285:11219-11226.
8. Giebel B., Corbeil D., Beckmann J., Höhn J., Freund D., Giesen K., Fischer J., Kögler G., Wernet P. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004, 104:2332-2338.
9. Gisler S.M., Kittanakom S., Fuster D., Wong V., Bertic M., Radanovic T., Hall R.A., Murer H., Biber J., Markovich D., et al. Monitoring protein-protein interactions between the mammalian integral membrane transporters and PDZ-interacting partners using a modified split-ubiquitin membrane yeast two-hybrid system. Mol. Cell. Proteomics 2008, 7:1362-1377.
10. Haggarty S.J., Koeller K.M., Wong J.C., Grozinger C.M., Schreiber S.L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 2003, 100:4389-4394.
11. Horst D., Scheel S.K., Liebmann S., Neumann J., Maatz S., Kirchner T., Jung A. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J. Pathol. 2009, 219:427-434.
12. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.F., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417:455-458.
13. Lee Y.S., Lim K.H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., Ordentlich P., Wang X.F., Counter C.M., Yao T.P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 2008, 68:7561-7569.
14. Li Y., Zhang X., Polakiewicz R.D., Yao T.P., Comb M.J. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J. Biol. Chem. 2008, 283:12686-12690.
15. Mak A.B., Ni Z., Hewel J.A., Chen G.I., Zhong G., Karamboulas K., Blakely K., Smiley S., Marcon E., Roudeva D., et al. A lentiviral functional proteomics approach identifies chromatin remodeling complexes important for the induction of pluripotency. Mol. Cell. Proteomics 2010, 9:811-823.
16. Mak A.B., Blakely K.M., Williams R.A., Penttilä P.A., Shukalyuk A.I., Osman K.T., Kasimer D., Ketela T., Moffat J. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J. Biol. Chem. 2011, 286:41046-41056.
17. Mak A.B., Nixon A.M., Moffat J. The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res. 2012, 72:1929-1934.
18. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
19. Maw M.A., Corbeil D., Koch J., Hellwig A., Wilson-Wheeler J.C., Bridges R.J., Kumaramanickavel G., John S., Nancarrow D., Röper K., et al. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum. Mol. Genet. 2000, 9:27-34.
20. Miraglia S., Godfrey W., Yin A.H., Atkins K., Warnke R., Holden J.T., Bray R.A., Waller E.K., Buck D.W. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
21. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124:1283-1298.
22. Namdar M., Perez G., Ngo L., Marks P.A. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc. Natl. Acad. Sci. USA 2010, 107:20003-20008.
23. Rappa G., Fodstad O., Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 2008, 26:3008-3017.
24. Reya T., Duncan A.W., Ailles L., Domen J., Scherer D.C., Willert K., Hintz L., Nusse R., Weissman I.L. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003, 423:409-414.
25. Röper K., Corbeil D., Huttner W.B. Retention of prominin in microvilli reveals distinct cholesterol-based lipid micro-domains in the apical plasma membrane. Nat. Cell Biol. 2000, 2:582-592.
26. Shan B., Yao T.P., Nguyen H.T., Zhuo Y., Levy D.R., Klingsberg R.C., Tao H., Palmer M.L., Holder K.N., Lasky J.A. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition. J. Biol. Chem. 2008, 283:21065-21073.
27. Shell S., Park S.M., Radjabi A.R., Schickel R., Kistner E.O., Jewell D.A., Feig C., Lengyel E., Peter M.E. Let-7 expression defines two differentiation stages of cancer. Proc. Natl. Acad. Sci. USA 2007, 104:11400-11405.
28. Snider J., Kittanakom S., Damjanovic D., Curak J., Wong V., Stagljar I. Detecting interactions with membrane proteins using a membrane two-hybrid assay in yeast. Nat. Protoc. 2010, 5:1281-1293.
29. Takenobu H., Shimozato O., Nakamura T., Ochiai H., Yamaguchi Y., Ohira M., Nakagawara A., Kamijo T. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011, 30:97-105.
30. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
31. Vermeulen L., De Sousa E Melo F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12:468-476.
32. Wang Y., Krivtsov A.V., Sinha A.U., North T.E., Goessling W., Feng Z., Zon L.I., Armstrong S.A. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010, 327:1650-1653.
33. Weigmann A., Corbeil D., Hellwig A., Huttner W.B. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc. Natl. Acad. Sci. USA 1997, 94:12425-12430.
34. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., Leary A.G., Olweus J., Kearney J., Buck D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
35. Zacchigna S., Oh H., Wilsch-Bräuninger M., Missol-Kolka E., Jászai J., Jansen S., Tanimoto N., Tonagel F., Seeliger M., Huttner W.B., et al. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J. Neurosci. 2009, 29:2297-2308.
36. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22:1168-1179.
37. Zhang Y., Gilquin B., Khochbin S., Matthias P. Two catalytic domains are required for protein deacetylation. J. Biol. Chem. 2006, 281:2401-2404.
38. Zhang X., Yuan Z., Zhang Y., Yong S., Salas-Burgos A., Koomen J., Olashaw N., Parsons J.T., Yang X.J., Dent S.R., et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol. Cell 2007, 27:197-213.
39. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., Cao C., Li N., Cheng H.L., Chua K., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 2008, 28:1688-1701.